A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety And Efficacy of SPI-1005 in Meniere's Disease
Phase of Trial: Phase II
Latest Information Update: 15 Oct 2018
At a glance
- Drugs Ebselen (Primary)
- Indications Meniere's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sound Pharmaceuticals
- 06 Sep 2018 Planned End Date changed from 1 Nov 2018 to 1 Dec 2018.
- 06 Sep 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Dec 2018.
- 10 Oct 2017 New trial record